O Dudeck1, M Zeile, P Reichardt, D Pink. 1. Department of Radiology, HELIOS Clinic Berlin-Buch, Berlin, Germany. oliver.dudeck@med.ovgu.de
Abstract
BACKGROUND: Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST). PATIENTS AND METHODS: Fifty-one patients with advanced GIST treated second line with sunitinib were evaluated with contrast-enhanced CT every 3 months. Response was rated according to RECIST and Choi criteria. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier analysis. RESULTS: According to RECIST, patients were categorized as complete response (CR; n = 0; 0%), partial remission (PR; n = 1; 2.0%), stable disease (SD; n = 37; 72.5%), and progressive disease (PD; n = 13; 25.5%) at 3 months. When Choi criteria were applied responses were CR (n = 0; 0%), PR (n = 16; 31.4%), SD (n = 21; 41.1%), and PD (n = 14; 27.5%). Despite these discrepancies, patients rated as SD with RECIST and PR as well as SD according to Choi criteria displayed similar PFS (41.3, 40.7, and 41.3 weeks, respectively) and OS (100.4, 91.6, and 108.0 weeks, respectively). Patients with PD had significantly shorter PFS (10.1 weeks for both criteria) and OS (29.1 weeks for RECIST; 28.9 weeks for Choi) regardless of the response classification applied. CONCLUSION: In contrast to absence of progression, discrimination of PR from SD with Choi criteria was of no predictive value.
BACKGROUND: Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST). PATIENTS AND METHODS: Fifty-one patients with advanced GIST treated second line with sunitinib were evaluated with contrast-enhanced CT every 3 months. Response was rated according to RECIST and Choi criteria. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier analysis. RESULTS: According to RECIST, patients were categorized as complete response (CR; n = 0; 0%), partial remission (PR; n = 1; 2.0%), stable disease (SD; n = 37; 72.5%), and progressive disease (PD; n = 13; 25.5%) at 3 months. When Choi criteria were applied responses were CR (n = 0; 0%), PR (n = 16; 31.4%), SD (n = 21; 41.1%), and PD (n = 14; 27.5%). Despite these discrepancies, patients rated as SD with RECIST and PR as well as SD according to Choi criteria displayed similar PFS (41.3, 40.7, and 41.3 weeks, respectively) and OS (100.4, 91.6, and 108.0 weeks, respectively). Patients with PD had significantly shorter PFS (10.1 weeks for both criteria) and OS (29.1 weeks for RECIST; 28.9 weeks for Choi) regardless of the response classification applied. CONCLUSION: In contrast to absence of progression, discrimination of PR from SD with Choi criteria was of no predictive value.
Authors: Annick D Van den Abbeele; Constantine Gatsonis; Daniel J de Vries; Yulia Melenevsky; Agnieszka Szot-Barnes; Jeffrey T Yap; Andrew K Godwin; Lori Rink; Min Huang; Meridith Blevins; Jorean Sicks; Burton Eisenberg; Barry A Siegel Journal: J Nucl Med Date: 2012-03-01 Impact factor: 10.057
Authors: Mary F Mulcahy; Armeen Mahvash; Marc Pracht; Amir H Montazeri; Steve Bandula; Robert C G Martin; Ken Herrmann; Ewan Brown; Darryl Zuckerman; Gregory Wilson; Tae-You Kim; Andrew Weaver; Paul Ross; William P Harris; Janet Graham; Jamie Mills; Alfonso Yubero Esteban; Matthew S Johnson; Constantinos T Sofocleous; Siddharth A Padia; Robert J Lewandowski; Etienne Garin; Philip Sinclair; Riad Salem Journal: J Clin Oncol Date: 2021-09-20 Impact factor: 44.544
Authors: Wayne L Monsky; Bedro Jin; Chris Molloy; Robert J Canter; Chin Shang Li; Tzu C Lin; Daniel Borys; Walter Mack; Isaac Kim; Michael H Buonocore; Abhijit J Chaudhari Journal: Anticancer Res Date: 2012-11 Impact factor: 2.480
Authors: Piotr Rutkowski; Elżbieta Bylina; Anna Klimczak; Tomasz Switaj; Sławomir Falkowski; Jacek Kroc; Iwona Lugowska; Magdalena Brzeskwiniewicz; Wojciech Melerowicz; Czesław Osuch; Ewa Mierzejewska; Kacper Wasielewski; Agnieszka Woźniak; Urszula Grzesiakowska; Zbigniew I Nowecki; Janusz A Siedlecki; Janusz Limon Journal: BMC Cancer Date: 2012-03-22 Impact factor: 4.430
Authors: Gaia Schiavon; Alessandro Ruggiero; Patrick Schöffski; Bronno van der Holt; Dave J Bekers; Karel Eechoute; Vincent Vandecaveye; Gabriel P Krestin; Jaap Verweij; Stefan Sleijfer; Ron H J Mathijssen Journal: PLoS One Date: 2012-11-02 Impact factor: 3.240